Literature DB >> 100818

Comparison of oral and intravenous methylphenidate.

D S Janowsky, P Leichner, P Clopton, L L Judd, D Parker, L Huey.   

Abstract

Oral methylphenidate (1.0 mg/kg) and intravenous methylphenidate (0.5 mg/kg) were compared as to their ability to increase behavioral activation, pulse, blood pressure, and serum growth hormone. Intravenous methylphenidate was considerably more effective than oral methylphenidate in activating behavior and in increasing pulse and blood pressure. Although oral methylphenidate appeared to increase behavioral activation, this effect was not statistically significant.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 100818     DOI: 10.1007/bf00428034

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  9 in total

1.  Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines.

Authors:  S H Snyder
Journal:  Am J Psychiatry       Date:  1973-01       Impact factor: 18.112

2.  Human growth hormone release during sleep: electroencephalographic correlation.

Authors:  D C Parker; J F Sassin; J W Mace; R W Gotlin; L G Rossman
Journal:  J Clin Endocrinol Metab       Date:  1969-06       Impact factor: 5.958

3.  Metabolism and disposition of methylphenidate-14C: studies in man and animals.

Authors:  B A Faraj; Z H Israili; J M Perel; M L Jenkins; S G Holtzman; S A Cucinell; P G Dayton
Journal:  J Pharmacol Exp Ther       Date:  1974-12       Impact factor: 4.030

4.  Provocation of schizophrenic symptoms by intravenous administration of methylphenidate.

Authors:  D S Janowsky; M K el-Yousel; J M Davis; H J Sekerke
Journal:  Arch Gen Psychiatry       Date:  1973-02

5.  Effect of route of administration on drug disposition.

Authors:  S Riegelman; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1973-10

6.  A comparison of the capacities of isomers of amphetamine, deoxypipradrol and methylphenidate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum and into adrenergic nerves of rabbit aorta.

Authors:  R M Ferris; F L Tang; R A Maxwell
Journal:  J Pharmacol Exp Ther       Date:  1972-06       Impact factor: 4.030

7.  Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man.

Authors:  W R Martin; J W Sloan; J D Sapira; D R Jasinski
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

8.  Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms.

Authors:  D S Janowsky; J M Davis
Journal:  Arch Gen Psychiatry       Date:  1976-03

9.  Comparative effects of d-amphetamine, l-amphetamine, and methylphenidate on mood in man.

Authors:  R C Smith; J M Davis
Journal:  Psychopharmacology (Berl)       Date:  1977-06-06       Impact factor: 4.530

  9 in total
  4 in total

Review 1.  Pharmacokinetics and clinical effectiveness of methylphenidate.

Authors:  H C Kimko; J T Cross; D R Abernethy
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

2.  Stability of extemporaneously prepared preservative-free methylphenidate 5 mg/mL intravenous solution.

Authors:  Megan E Barra; Brian L Edlow; James T Lund; Katherine S DeSanctis; John Vetrano; Cherylann Reilly-Tremblay; Edlyn R Zhang; Yelena G Bodien; Emery N Brown; Ken Solt
Journal:  Am J Health Syst Pharm       Date:  2022-02-18       Impact factor: 2.980

3.  Provocative tests with psychostimulant drugs in schizophrenia.

Authors:  J A Lieberman; J M Kane; J Alvir
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Personalized Connectome Mapping to Guide Targeted Therapy and Promote Recovery of Consciousness in the Intensive Care Unit.

Authors:  Brian L Edlow; Megan E Barra; David W Zhou; Andrea S Foulkes; Samuel B Snider; Zachary D Threlkeld; Sourish Chakravarty; John E Kirsch; Suk-Tak Chan; Steven L Meisler; Thomas P Bleck; Joseph J Fins; Joseph T Giacino; Leigh R Hochberg; Ken Solt; Emery N Brown; Yelena G Bodien
Journal:  Neurocrit Care       Date:  2020-08-13       Impact factor: 3.210

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.